Food for thought⋯: Animal use for science in Europe

Altex

Volumn 32, Issue 4, 2015, Pages 261-274

  Daneshian, Mardas ^a   Busquet, Francois ^a   Hartung, Thomas ^a,b   Leist, Marcel ^a  

^a UNIVERSITY OF KONSTANZ   (Germany)

^b JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Alternative methods; Animal statistics; Animal testing; Replacement; Stem cells

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL RIGHTS; ANIMAL TESTING ALTERNATIVE; ANIMAL USE; ANIMAL WELFARE; ARTICLE; CHEMICAL SAFETY; EUROPE; EXPERIMENTAL ANIMAL; LEGAL ASPECT; MEDICAL RESEARCH; NONHUMAN; RISK ASSESSMENT; SCIENCE; TRANSGENIC ANIMAL; ANIMAL; EUROPEAN UNION; TRENDS;

ANIMAL TESTING ALTERNATIVES; ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANIMALS, LABORATORY; BIOMEDICAL RESEARCH; EUROPEAN UNION;

EID: 84946721769     PISSN: 1868596X     EISSN: 18688551     Source Type: Journal    
DOI: 10.4573/altex.1509081     Document Type: Article

References (134)

1. Adler, S., Basketter, D., Creton, S. et al. (2011). Alternative (non-animal) methods for cosmetics testing: Current status and future prospects-2010. Arch Toxicol 85, 367-485. http://dx.doi.org/10.1007/s00204-011-0693-2
2. Alepee, N., Bahinski, A., Daneshian, M. et al. (2014). State-of-the-art of 3D cultures (organs-on-a-chip) in safety testing and pathophysiology. ALTEX 31, 441-477. http://dx.doi.org/10.14573/altex1406111
3. Andersen, M. E., Betts, K., Dragan, Y. et al. (2014). Developing microphysiological systems for use as regulatory tools-challenges and opportunities. ALTEX 31, 364-367. http://dx.doi.org/10.14573/altex.1405151
4. Anway, M. D., Cupp, A. S., Uzumcu, M. et al. (2005). Epigenetic transgenerational actions of endocrine disruptors and male fertility. Science 308, 1466-1469. http://dx.doi.org/10.1126/science.1108190
5. Bailey, J. and Taylor, K. (2009). The SCHER report on non-human primate research-biased and deeply flawed. Altern Lab Anim 37, 427-435.
6. Bal-Price, A., Crofton, K. M., Leist, M. et al. (2015). International STakeholder NETwork (ISTNET): Creating a developmental neurotoxicity (DNT) testing road map for regulatory purposes. Arch Toxicol 89, 269-287. http://dx.doi.org/10.1007/s00204-015-1464-2
7. Balmer, N. V., Weng, M. K., Zimmer, B. et al. (2012). Epigenetic changes and disturbed neural development in a human embryonic stem cell-based model relating to the fetal valproate syndrome. Hum Mol Genet 21, 4104-4114. http://dx.doi.org/10.1093/hmg/dds239
8. Balmer, N. V., Klima, S., Rempel, E. et al. (2014). From transient transcriptome responses to disturbed neurodevelopment: Role of histone acetylation and methylation as epigenetic switch between reversible and irreversible drug effects. Arch Toxicol 88, 1451-1468. http://dx.doi.org/10.1007/s00204-014-1279-6
9. Balmer, N. V. and Leist, M. (2014). Epigenetics and transcriptomics to detect adverse drug effects in model systems of human development. Basic Clin Pharmacol Toxicol 115, 59-68. http://dx.doi.org/10.1111/bcpt.12203
10. Basketter, D. A., Clewell, H., Kimber, I. et al. (2012). A roadmap for the development of alternative (non-animal) methods for systemic toxicity testing - The report. ALTEX 29, 3-91. http://dx.doi.org/10.14573/altex.2012.1.003
11. BMEL (2014). Versuchstierzahlen 2013. Bundesministerium für Ernährung und Landwirtschaft. 15.
12. Bolt, H. M. (2013). Developmental neurotoxicity testing with human embryonic stem cell-derived in vitro systems: The novel FP7 ESNATS tests are available. Arch Toxicol 87, 5-6. http://dx.doi.org/10.1007/s00204-012-0982-4
13. Bottini, A. A. and Hartung, T. (2009). Food for thought⋯ on the economics of animal testing. ALTEX 26, 3-16. http://www.altex.ch/resources/altex-2009-1-3-16-FFT-Hartung.pdf
14. Bouhifd, M., Hartung, T., Hogberg, H. T. et al. (2013). Review: Toxicometabolomics. J Appl Toxicol 33, 1365-1383. http://dx.doi.org/10.1002/jat.2874
15. Bouhifd, M., Hogberg, H. T., Kleensang, A. et al. (2014). Mapping the human toxome by systems toxicology. Basic Clin Pharmacol Toxicol 115, 24-31. http://dx.doi.org/10.1111/bcpt.12198
16. Bouhifd, M., Andersen, M. E., Baghdikian, C. et al. (2015). The human toxome project. ALTEX 32, 112-124. http://dx.doi.org/10.14573/altex.1502091
17. Bouvier d'Yvoire, M., Bremer, S., Casati, S. et al. (2012). ECVAM and new technologies for toxicity testing. Adv Exp Med Biol 745, 154-180. http://dx.doi.org/10.1007/978-1-4614-3055-1-10
18. Box, R. J. and Spielmann, H. (2005). Use of the dog as non-rodent test species in the safety testing schedule associated with the registration of crop and plant protection products (pesticides): Present status. Arch Toxicol 79, 615-626. http://dx.doi.org/10.1007/s00204-005-0678-0
19. BUAV (2011). Meeting the Deadline of the 2013 EU Marketing Ban-A Scientific Review of Non-Animal Tests for Cosmetics British Union for the Abolition of Vivisection. 16.
20. Burm, S. M., Prins, J. B., Langermans, J. et al. (2014). Alternative methods for the use of non-human primates in biomedical research. ALTEX 31, 520-529. http://dx.doi.org/10.14573/altex.1406231
21. Buta, C., David, R., Dressel, R. et al. (2013). Reconsidering pluripotency tests: Do we still need teratoma assays? Stem Cell Res 11, 552-562. http://dx.doi.org/10.1016/j.scr.2013.03.001
22. Cavanaugh, S. E., Pippin, J. J. and Barnard, N. D. (2014). Animal models of Alzheimer disease: Historical pitfalls and a path forward. ALTEX 31, 279-302. http://dx.doi.org/10.14573/altex.1310071
23. Chandrasekera, P. C. and Pippin, J. J. (2014). Of rodents and men: Species-specific glucose regulation and type 2 diabetes research. ALTEX 31, 157-176. http://dx.doi.org/10.14573/1309231
24. Collins, F. S., Gray, G. M. and Bucher, J. R. (2008). Transforming environmental health protection. Science 319, 906-907. http://dx.doi.org/10.1126/science.1154619
25. Corti, S., Faravelli, I., Cardano, M. et al. (2015). Human pluripotent stem cells as tools for neurodegenerative and neurodevelopmental disease modeling and drug discovery. Expert Opin Drug Discov 10, 615-629. http://dx.doi.org/10.1517/17460441.2015.1037737
26. Cunningham, M. L. (2002). A mouse is not a rat is not a human: Species differences exist. Toxicol Sci 70, 157-158. http://dx.doi.org/10.1093/toxsci/70.2.157
27. Daneshian, M., Akbarsha, M. A., Blaauboer, B. et al. (2011). A framework program for the teaching of alternative methods (replacement, reduction, refinement) to animal experimentation. ALTEX 28, 341-352. http://dx.doi.org/10.14573/altex.2011.4.341
28. Daneshian, M., Botana, L. M., Dechraoui Bottein, M. Y. et al. (2013). A roadmap for hazard monitoring and risk assessment of marine biotoxins on the basis of chemical and biological test systems. ALTEX 30, 487-545. http://dx.doi.org/10.14573/altex.2013.4.487
29. Daston, G., Knight, D. J., Schwarz, M. et al. (2015). SEURAT: Safety Evaluation Ultimately Replacing Animal Testing-recommendations for future research in the field of predictive toxicology. Arch Toxicol 89, 15-23. http://dx.doi.org/10.1007/s00204-014-1421-5
30. Dellarco, V. L., Rowland, J. and May, B. (2010). A retrospective analysis of toxicity studies in dogs and impact on the chronic reference dose for conventional pesticide chemicals. Crit Rev Toxicol 40, 16-23. http://dx.doi.org/10.3109/10408440903401529
31. De Los Angeles, A., Ferrari, F., Xi, R. (2015). Hallmarks of pluripotency. Nature 525, 469-78. http://dx.doi.org/10.1038/nature15515
32. Diede, S. J., Yao, Z., Keyes, C. C. et al. (2013). Fundamental differences in promoter CpG island DNA hypermethylation between human cancer and genetically engineered mouse models of cancer. Epigenetics 8, 1254-1260. http://dx.doi.org/10.4161/epi.26486
33. Dietrich, D. R., Aulock, S., Marquardt, H. et al. (2013). Scientifically unfounded precaution drives European Commission's recommendations on EDC regulation, while defying common sense, well-established science and risk assessment principles. Chem Biol Interact 205, A1-5. http://dx.doi.org/10.1016/j.cbi.2013.07.001
34. Dix, D. J., Houck, K. A., Martin, M. T. et al. (2007). The ToxCast program for prioritizing toxicity testing of environmental chemicals. Toxicol Sci 95, 5-12. http://dx.doi.org/10.1093/toxsci/kfl103
35. EU-European Union (2008). Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006. 1272/2008 1355.
36. EU (2009). Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products. 1223/2009 151.
37. EU (2012). Regulation (EU) No 528/2012 of the European Parliament and of the Council of 22 May 2012 concerning the making available on the market and use of biocidal products. 528/2012 123.
38. EC-European Commission (2001). EUROBAROMETER 55.2, Europeans, science and technology, Brussels, Belgium. http://ec.europa.eu/public-opinion/archives/ebs/ebs-154-en.pdf
39. EC (2005). Special Eurobarometer 225, Social values, Science and Technology, Brussels, Belgium. http://ec.europa.eu/public-opinion/archives/ebs/ebs-225-report-en.pdf
40. EC (2010). Special Eurobarometer 340, Science and Technology, Brussels, Belgium. http://ec.europa.eu/public-opinion/archives/ebs/ebs-340-en.pdf
41. EC (2013). Seventh Report on the Statistics on the Number of Animals used for Experimental and other Scientific Purposes in the Member States of the European Union. http://ec.europa.eu/environment/chemicals/lab-animals/reports-en.htm
42. ECHA (2014). The use of alternatives to testing on animals for REACH. European Chemicals Agenc. ECHA-14-A-08-EN. https://echa.europa.eu/documents/10162/13639/alternatives-test-animals-2014-summary-en.pdf
43. Efremova, L., Schildknecht, S., Adam, M. et al. (2015). Prevention of the degeneration of human dopaminergic neurons in an astrocyte co-culture system allowing endogenous drug metabolism. Br J Pharmacol 172, 4119-4132. http://dx.doi.org/10.1111/bph.13193
44. Embry, M. R., Bachman, A. N., Bell, D. R. et al. (2014). Risk assessment in the 21st century: Roadmap and matrix. Crit Rev Toxicol 44, Suppl 3, 6-16. http://dx.doi.org/10.3109/10408444.2014.931924
45. Fabre, K. M., Livingston, C. and Tagle, D. A. (2014). Organs-on-chips (microphysiological systems): Tools to expedite efficacy and toxicity testing in human tissue. Exp Biol Med (Maywood) 239, 1073-1077. http://dx.doi.org/10.1177/1535370214538916
46. Fernandez-Salas, E., Wang, J., Molina, Y. et al. (2012). Botulinum neurotoxin serotype A specific cell-based potency assay to replace the mouse bioassay. PLoS One 7, e49516. http://dx.doi.org/10.1371/journal.pone.0049516
47. Ferrario, D. and Rabbit, R. R. (2012). Analysis of the proposed EU regulation concerning biocide products and its opportunities for alternative approaches and a toxicology for the 21st century (The report). ALTEX 29, 157-172. http://dx.doi.org/10.14573/altex.2012.2.157
48. Giri, S. and Bader, A. (2015). A low-cost, high-quality new drug discovery process using patient-derived induced pluripotent stem cells. Drug Discov Today 20, 37-49. http://dx.doi.org/10.1016/j.drudis.2014.10.011
49. Gocht, T., Berggren, E., Ahr, H. J. et al. (2015). The SEURAT-1 approach towards animal free human safety assessment. ALTEX 32, 9-24. http://dx.doi.org/10.14573/altex.1408041
50. Gruber, F. P. and Hartung, T. (2004). Alternatives to animal experimentation in basic research. ALTEX 21, Suppl 1, 3-31. http://www.altex.ch/resources/gruberhartung-suppl-2004.pdf
51. Gruber, F. P. (2011). The Basel Declaration: A critical appraisal. ALTEX 28, 353-354. http://dx.doi.org/10.14573/altex.2011.4.353
52. Hartman, K. G., Bortner, J. D., Jr., Falk, G. W. et al. (2014). Modeling human gastrointestinal inflammatory diseases using microphysiological culture systems. Exp Biol Med (Maywood) 239, 1108-1123. http://dx.doi.org/10.1177/1535370214529388
53. Hartung, T. (2007). Food for thought⋯ on validation. ALTEX 24, 67-73. http://www.altex.ch/resources/altex-2007-2-67-73-HartungE.pdf
54. Hartung, T. (2008). Food for thought⋯ on alternative methods for cosmetics safety testing. ALTEX 25, 147-162. http://www.altex.ch/resources/altex-2008-3-147-162-FFT-HartungE.pdf
55. Hartung, T. and Leist, M. (2008). Food for thought⋯ on the evolution of toxicology and the phasing out of animal testing. ALTEX 25, 91-96. http://www.altex.ch/resources/altex-2008-2-91-96-FFT-HartungE.pdf
56. Hartung, T. and Rovida, C. (2009a). Chemical regulators have overreached. Nature 460, 1080-1081. http://dx.doi.org/10.1038/4601080a
57. Hartung, T. and Rovida, C. (2009b). That which must not, can not be⋯ A reply to the EChA and EDF responses to the REACH analysis of animal use and costs. ALTEX 26, 307-311. http://www.altex.ch/resources/altex-2009-4-307-311-Hartung.pdf
58. Hartung, T. (2010a). Comparative analysis of the revised Directive 2010/63/EU for the protection of laboratory animals with its predecessor 86/609/EEC - a The report. ALTEX 27, 285-303. http://www.altex.ch/resources/altex-2010-4-285-303-Hartung21.pdf
59. Hartung, T. (2010b). Food for thought⋯ on alternative methods for chemical safety testing. ALTEX 27, 3-14. http://www.altex.ch/resources/altex-2010-1-3-14-FFT-Hartung.pdf
60. Hartung, T. (2011). From alternative methods to a new toxicology. Eur J Pharm Biopharm 77, 338-349. http://dx.doi.org/10.1016/j.ejpb.2010.12.027
61. Hartung, T., Blaauboer, B. J., Bosgra, S. et al. (2011). An expert consortium review of the EC-commissioned report "alternative (non-animal) methods for cosmetics testing: Current status and future prospects-2010". ALTEX 28, 183-209. http://dx.doi.org/10.14573/altex.2011.3.183
62. Hartung, T. (2012). Pathways of Toxicity Mapping Center (PoToMaC). In H. Spielmann and T. Seidle (eds.), Alternative Testing Strategies: Progress Report 2012 & AXLR8-3 Workshop Report on a "Roadmap to Next Generation Safety Testing Under Horizon 2020." (165-169). http://axlr8.eu/assets/axlr8-progress-report-2012.pdf
63. Hartung, T., van Vliet, E., Jaworska, J. et al. (2012). Systems toxicology. ALTEX 29, 119-128. http://dx.doi.org/10.14573/altex.2012.2.119
64. Hartung, T. and Zurlo, J. (2012). Alternative approaches for medical countermeasures to biological and chemical terrorism and warfare. ALTEX 29, 251-260. http://dx.doi.org/10.14573/altex.2012.3.251
65. Hartung, T., Luechtefeld, T., Maertens, A. et al. (2013). Integrated testing strategies for safety assessments. ALTEX 30, 3-18. http://dx.doi.org/10.14573/altex.2013.1.003
66. Hartung, T. (2014). 3D - a new dimension of in vitro research. Adv Drug Deliv Rev 69-70, vi. http://dx.doi.org/10.1016/j.addr.2014.04.003
67. Hasiwa, N., Bailey, J., Clausing, P. et al. (2011). Critical evaluation of the use of dogs in biomedical research and testing in Europe. ALTEX 28, 326-340. http://dx.doi.org/10.14573/altex.2011.4.326
68. Inoue, H., Nagata, N., Kurokawa, H. et al. (2014). iPS cells: A game changer for future medicine. EMBO J 33, 409-417. http://dx.doi.org/10.1002/embj.201387098
69. Juberg, D. R., Borghoff, S. J., Becker, R. A. et al. (2014). The workshop report-lessons learned, challenges, and opportunities: The U.S. Endocrine Disruptor Screening Program. ALTEX 31, 63-78. http://dx.doi.org/10.14573/altex.1309171
70. Judson, R., Kavlock, R., Martin, M. et al. (2013). Perspectives on validation of high-throughput assays supporting 21st century toxicity testing. ALTEX 30, 51-56. http://dx.doi.org/10.14573/altex.2013.1.051
71. Judson, R., Houck, K., Martin, M. et al. (2014). In vitro and modelling approaches to risk assessment from the U.S. Environmental Protection Agency ToxCast programme. Basic Clin Pharmacol Toxicol 115, 69-76. http://dx.doi.org/10.1111/bcpt.12239
72. Kandarova, H. and Letasiova, S. (2011). Alternative methods in toxicology: Pre-validated and validated methods. Interdiscip Toxicol 4, 107-113. http://dx.doi.org/10.2478/v10102-011-0018-6
73. Karakikes, I., Termglinchan, V. and Wu, J. C. (2014). Human-induced pluripotent stem cell models of inherited cardiomyopathies. Curr Opin Cardiol 29, 214-219. http://dx.doi.org/10.1097/HCO.0000000000000049
74. Kavlock, R. and Dix, D. (2010). Computational toxicology as implemented by the U.S. EPA: Providing high throughput decision support tools for screening and assessing chemical exposure, hazard and risk. J Toxicol Environ Health B Crit Rev 13, 197-217. http://dx.doi.org/10.1080/10937404.2010.483935
75. Kim, H. S., Bernitz, J. M., Lee, D. F. et al. (2014). Genomic editing tools to model human diseases with isogenic pluripotent stem cells. Stem Cells Dev 23, 2673-2686. http://dx.doi.org/10.1089/scd.2014.0167
76. Kleensang, A., Maertens, A., Rosenberg, M. et al. (2014). The workshop report: Pathways of toxicity. ALTEX 31, 53-61. http://dx.doi.org/10.14573/altex.1309261
77. Kleinstreuer, N. C., Yang, J., Berg, E. L. et al. (2014). Phenotypic screening of the ToxCast chemical library to classify toxic and therapeutic mechanisms. Nat Biotechnol 32, 583-591. http://dx.doi.org/10.1038/nbt.2914
78. Klip, H., Verloop, J., van Gool, J. D. et al. (2002). Hypospadias in sons of women exposed to diethylstilbestrol in utero: A cohort study. Lancet 359, 1102-1107. http://dx.doi.org/10.1016/S0140-6736(02)08152-7
79. Knudsen, T., Martin, M., Chandler, K. et al. (2013). Predictive models and computational toxicology. Methods Mol Biol 947, 343-374. http://dx.doi.org/10.1007/978-1-62703-131-8-26
80. Ko, H. C. and Gelb, B. D. (2014). Concise review: Drug discovery in the age of the induced pluripotent stem cell. Stem Cells Transl Med 3, 500-509. http://dx.doi.org/10.5966/sctm.2013-0162
81. Krug, A. K., Kolde, R., Gaspar, J. A. et al. (2013). Human embryonic stem cell-derived test systems for developmental neurotoxicity: A transcriptomics approach. Arch Toxicol 87, 123-143. http://dx.doi.org/10.1007/s00204-012-0967-3
82. Kuegler, P. B., Zimmer, B., Waldmann, T. et al. (2010). Markers of murine embryonic and neural stem cells, neurons and astrocytes: Reference points for developmental neurotoxicity testing. ALTEX 27, 16-42. http://www.altex.ch/resources/altex-2010-1-16-41-Kuegler.pdf
83. Lancaster, M. A. and Knoblich, J. A. (2014). Organogenesis in a dish: Modeling development and disease using organoid technologies. Science 345, 1247125. http://dx.doi.org/10.1126/science.1247125
84. Leist, M., Hartung, T. and Nicotera, P. (2008a). The dawning of a new age of toxicology. ALTEX 25, 103-114. http://www.altex.ch/resources/altex-2008-2-103-114-LeistE.pdf
85. Leist, M., Kadereit, S. and Schildknecht, S. (2008b). Food for thought⋯ on the real success of 3R approaches. ALTEX 25, 17-24. http://www.altex.ch/resources/altex-2008-1-17-24-FFT-LeistE.pdf
86. Leist, M., Hasiwa, N., Daneshian, M. et al. (2012a). Validation and quality control of replacement alternatives-current status and future challenges. Toxicol Res 1, 8-22. http://dx.doi. org/10.1039/C2TX20011B
87. Leist, M., Lidbury, B. A., Yang, C. et al. (2012b). Novel technologies and an overall strategy to allow hazard assessment and risk prediction of chemicals, cosmetics, and drugs with animal-free methods. ALTEX 29, 373-388. http://dx.doi.org/10.14573/altex.2012.4.373
88. Leist, M. and Hartung, T. (2013). Inflammatory findings on species extrapolations: Humans are definitely no 70-kg mice. ALTEX 30, 227-230. http://dx.doi.org/10.14573/altex.2013.2.227
89. Leist, M., Ringwald, A., Kolde, R. et al. (2013). Test systems of developmental toxicity: State-of-the art and future perspectives. Arch Toxicol 87, 2037-2042. http://dx.doi.org/10.1007/s00204-013-1154-x
90. Leist, M., Hasiwa, N., Rovida, C. et al. (2014). Consensus report on the future of animal-free systemic toxicity testing. ALTEX 31, 341-356. http://dx.doi.org/10.14573/altex.1406091
91. Li, M., Suzuki, K., Kim, N. Y. et al. (2014). A cut above the rest: Targeted genome editing technologies in human pluripotent stem cells. J Biol Chem 289, 4594-4599. http://dx.doi.org/10.1074/jbc.R113.488247
92. Li, X., Xia, B. L., Li, W. et al. (2015). Assessing reprogramming by chimera formation and tetraploid complementation. Methods Mol Biol 1222, 247-254. http://dx.doi.org/10.1007/978-1-4939-1594-1-18
93. Lin, S., Lin, Y., Nery, J. R. et al. (2014). Comparison of the transcriptional landscapes between human and mouse tissues. Proc Natl Acad Sci U S A 111, 17224-17229. http://dx.doi.org/10.1073/pnas.1413624111
94. Lindl, T., Gross, U., Ruhdel, I. et al. (2012). Guidance on determining indispensability and balancing potential benefits of animal experiments with costs to the animals with specific consideration of EU directive 2010/63/EU. ALTEX 29, 219-228. http://dx.doi.org/10.14573/altex.2012.2.219
95. Marx, U., Walles, H., Hoffmann, S. et al. (2012). 'Human-on-a-chip' developments: A translational cutting-edge alternative to systemic safety assessment and efficiency evaluation of substances in laboratory animals and man? Altern Lab Anim 40, 235-257.
96. Materne, E. M., Maschmeyer, I., Lorenz, A. K. et al. (2015). The multi-organ chip - a microfluidic platform for long-term multi-tissue coculture. J Vis Exp e52526. http://dx.doi.org/10.3791/52526
97. Muller, F. J., Brandl, B. and Loring, J. F. (2008). Assessment of human pluripotent stem cells with PluriTest. In StemBook. Cambridge (MA). http://www.ncbi.nlm.nih.gov/pubmed/23658970
98. Muller, F. J., Goldmann, J., Loser, P. et al. (2010). A call to standardize teratoma assays used to define human pluripotent cell lines. Cell Stem Cell 6, 412-414. http://dx.doi.org/10.1016/j.stem.2010.04.009
99. Neumann, J.-M. (2015). The legal status of animals in the French Civil Code - The recognition by the French Civil Code that animals are living and sentient beings: Symbolic move, evolution or revolution? GJAL 1, 13.
100. NRC-National Research Council (2007). Toxicity Testing in the 21st Century: A Vision and a Strategy. T. N. A. Press
101. Olson, T. S. and Ley, K. (2002). Chemokines and chemokine receptors in leukocyte trafficking. Am J Physiol Regul Integr Comp Physiol 283, R7-28. http://dx.doi.org/10.1152/ajpregu.00738.2001
102. Pastoor, T. P., Bachman, A. N., Bell, D. R. et al. (2014). A 21st century roadmap for human health risk assessment. Crit Rev Toxicol 44, Suppl 3, 1-5. http://dx.doi.org/10.3109/10408444.2014.931923
103. Patlewicz, G., Ball, N., Becker, R. A. et al. (2014). Read-across approaches-misconceptions, promises and challenges ahead. ALTEX 31, 387-396. http://dx.doi.org/10.14573/altex.1410071
104. Piersma, A. H. (2015). Innovative testing in reproductive toxicology - the ChemScreen experience. Reprod Toxicol 55, 1-2. http://dx.doi.org/10.1016/j.reprotox.2014.10.025
105. Quinnies, K. M., Doyle, T. J., Hee Kim, K. et al. (2015). Transgenerational effects of di-(2-ethylhexyl) phthalate, DEHP, on stress hormones and behavior. Endocrinology 156, 3077-3083. http://dx.doi.org/10.1210/EN.2015-1326
106. Ramirez, T., Daneshian, M., Kamp, H. et al. (2013). Metabolomics in toxicology and preclinical research. ALTEX 30, 209-225. http://dx.doi.org/10.14573/altex.2013.2.209
107. Rovida, C. and Hartung, T. (2009). Re-evaluation of animal numbers and costs for in vivo tests to accomplish REACH legislation requirements for chemicals - a report by the transatlantic think tank for toxicology (The). ALTEX 26, 187-208. http://www.altex.ch/resources/altex-2009-3-187-208-Rovida.pdf
108. Rovida, C. (2010). Food for thought⋯ why no new in vitro tests will be done for REACH by registrants. ALTEX 27, 175-183. http://www.altex.ch/resources/altex-2010-3-175-183-FFT-Rovida.pdf
109. Rovida, C., Vivier, M., Garthoff, B. et al. (2014). ESNATS conference - the use of human embryonic stem cells for novel toxicity testing approaches. Altern Lab Anim 42, 97-113.
110. Rovida, C., Alepee, N., Api, A. M. et al. (2015). Integrated Testing Strategies (ITS) for safety assessment. ALTEX 32, 25-40. http://dx.doi.org/10.14573/altex.1411011
111. Sauer, J. M., Hartung, T., Leist, M. et al. (2015). Systems toxicology: The future of risk assessment. Int J Toxicol. http://dx.doi.org/10.1177/1091581815576551
112. Schadt, E. E., Buchanan, S., Brennand, K. J. et al. (2014). Evolving toward a human-cell based and multiscale approach to drug discovery for CNS disorders. Front Pharmacol 5, 252. http://dx.doi.org/10.3389/fphar.2014.00252
113. Schildknecht, S., Gerding, H. R., Karreman, C. et al. (2013a). Oxidative and nitrative alpha-synuclein modifications and proteostatic stress: Implications for disease mechanisms and interventions in synucleinopathies. J Neurochem 125, 491-511. http://dx.doi.org/10.1111/jnc.12226
114. Schildknecht, S., Karreman, C., Pöltl, D. et al. (2013b). Generation of genetically-modified human differentiated cells for toxicological tests and the study of neurodegenerative diseases. ALTEX 30, 427-444. http://www.altex.ch/resources/altex-2013-4-427444-Schildknecht.pdf
115. Schneider, S., Kaufmann, W., Buesen, R. et al. (2008). Vinclozolin - the lack of a transgenerational effect after oral maternal exposure during organogenesis. Reprod Toxicol 25, 352-360. http://dx.doi.org/10.1016/j.reprotox.2008.04.001
116. Scholz, D., Chernyshova, Y. and Leist, M. (2013). Control of Abeta release from human neurons by differentiation status and RET signaling. Neurobiol Aging 34, 184-199. http://dx.doi.org/10.1016/j.neurobiolaging.2012.03.012
117. Singh, V. K., Kalsan, M., Kumar, N. et al. (2015). Induced pluripotent stem cells: Applications in regenerative medicine, disease modeling, and drug discovery. Front Cell Dev Biol 3, 2. http://dx.doi.org/10.3389/fcell.2015.00002
118. Smirnova, L., Hogberg, H. T., Leist, M. et al. (2014). Developmental neurotoxicity-challenges in the 21st century and in vitro opportunities. ALTEX 31, 129-156. http://dx.doi.org/10.14573/altex.1403271
119. Sturla, S. J., Boobis, A. R., FitzGerald, R. E. et al. (2014). Systems toxicology: From basic research to risk assessment. Chem Res Toxicol 27, 314-329. http://dx.doi.org/10.1021/tx400410s
120. Sturla, S. J. and Hollenberg, P. (2014). Systems toxicology: A special issue. Chem Res Toxicol 27, 311. http://dx.doi.org/10.1021/tx500024u
121. Sung, J. H., Srinivasan, B., Esch, M. B. et al. (2014). Using physiologically-based pharmacokinetic-guided "body-on-a-chip" systems to predict mammalian response to drug and chemical exposure. Exp Biol Med (Maywood) 239, 1225-1239. http://dx.doi.org/10.1177/1535370214529397
122. Szyf, M. (2015). Nongenetic inheritance and transgenerational epigenetics. Trends Mol Med 21, 134-144. http://dx.doi.org/10.1016/j.molmed.2014.12.004
123. Taylor, K., Gordon, N., Langley, G. et al. (2008). Estimates for worldwide laboratory animal use in 2005. Altern Lab Anim 36, 327-342.
124. Taylor, K., Casalegno, C. and Stengel, W. (2011). A critique of the EC's expert (draft) reports on the status of alternatives for cosmetics testing to meet the 2013 deadline. ALTEX 28, 131-148. http://dx.doi.org/10.14573/altex.2011.2.131
125. Taylor, K. (2014). EU member state government contribution to alternative methods. ALTEX 31, 215-218. http://dx.doi.org/10.14573/altex.1401061
126. Tollefsen, K. E., Scholz, S., Cronin, M. T. et al. (2014). Applying Adverse Outcome Pathways (AOPs) to support Integrated Approaches to Testing and Assessment (IATA). Regul Toxicol Pharmacol 70, 629-640. http://dx.doi.org/10.1016/j.yrtph.2014.09.009
127. van der Burg, B., Wedebye, E. B., Dietrich, D. R. et al. (2015). The ChemScreen project to design a pragmatic alternative approach to predict reproductive toxicity of chemicals. Reprod Toxicol 55, 114-123. http://dx.doi.org/10.1016/j.reprotox.2015.01.008
128. van Vliet, E., Daneshian, M., Beilmann, M. et al. (2014). Current approaches and future role of high content imaging in safety sciences and drug discovery. ALTEX 31, 479-493. http://dx.doi.org/10.14573/altex.1405271
129. von Roten, F. C. (2009). European attitudes towards animal research: Overview and consequences for science. Science, Technology & Society 14:2, 349-364. http://dx.doi.org/10.1177/097172180901400207
130. von Roten, F. C. (2013). Public perceptions of animal experimentation across Europe. Public Underst Sci 22, 691-703. http://dx.doi.org/10.1177/0963662511428045
131. Wedebye, E. B., Dybdahl, M., Nikolov, N. G. et al. (2015). QSAR screening of 70,983 REACH substances for genotoxic carcinogenicity, mutagenicity and developmental toxicity in the ChemScreen project. Reprod Toxicol 55, 64-72. http://dx.doi.org/10.1016/j.reprotox.2015.03.002
132. Whelan, M. and Andersen, M. (2013). Toxicity Pathways-from concepts to application in chemical safety assessment. Scientific and Policy Report by the Joint Research Centre of the European Commission. European Commission, Joint Research Centre, Institute for Health and Consumer Protection.
133. Yue, F., Cheng, Y., Breschi, A. et al. (2014). A comparative encyclopedia of DNA elements in the mouse genome. Nature 515, 355-364. http://dx.doi.org/10.1038/nature13992
134. Zimmer, B., Pallocca, G., Dreser, N. et al. (2014). Profiling of drugs and environmental chemicals for functional impairment of neural crest migration in a novel stem cell-based test battery. Arch Toxicol 88, 1109-1126. http://dx.doi.org/10.1007/s00204-014-1231-9